Changes in physician antipsychotic prescribing preferences, 2002-2007

Psychiatric Services

Volumn 65, Issue 3, 2014, Pages 315-322

  Donohue, Julie ^a   O'Malley, A James ^b   Horvitz Lennon, Marcela ^c   Taub, Anna Levine ^d   Berndt, Ernst R ^e   Huskamp, Haiden A ^f  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^c RAND CORPORATION   (United States)

^d NORTHEASTERN UNIVERSITY   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE;

ADULT; ARTICLE; COMPARATIVE EFFECTIVENESS; DATA BASE; FEMALE; HUMAN; MALE; MEDICAL SOCIETY; PHYSICIAN; PRESCRIPTION; PSYCHIATRIST; CLINICAL PRACTICE; DECISION MAKING; DRUG UTILIZATION; HEALTH SERVICES RESEARCH; LONGITUDINAL STUDY; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; TIME; TRENDS; UNITED STATES;

ADULT; ANTIPSYCHOTIC AGENTS; CHOICE BEHAVIOR; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HEALTH SERVICES RESEARCH; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; TIME FACTORS; UNITED STATES;

EID: 84901940950     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201200536     Document Type: Article

References (46)

1. Greenberg PE, Kessler RC, Birnbaum HG, et al: The economic burden of depression in the United States: how did it change between 1990 and 2000? Journal of Clinical Psychiatry 64:1465-1475, 2003 (Pubitemid 41270106)
2. Wu EQ, Birnbaum HG, Shi L, et al: The economic burden of schizophrenia in the United States in 2002. Journal of Clinical Psychiatry 66:1122-1129, 2005 (Pubitemid 41442278)
3. Leslie DL, Mohamed S, Rosenheck RA: Off-label use of antipsychotic medications in the department of Veterans Affairs health care system. Psychiatric Services 60: 1175-1181, 2009
4. Gallini A, Huskamp HA, Donohue JM: Diffusion of antipsychotics in the US and French markets, 1998-2008. Psychiatric Services 64:680-687, 2013
5. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209-1223, 2005 (Pubitemid 41345943)
6. Kraemer HC, Glick ID, Klein DF: Clinical trials design lessons from the CATIE study. American Journal of Psychiatry 166:1222-1228, 2009
7. Lieberman JA, Stroup TS: The NIMHCATIE Schizophrenia Study: what did we learn? American Journal of Psychiatry 168:770-775, 2011
8. Lewis S, Lieberman JA: CATIE and CUtLASS: can we handle the truth? British Journal of Psychiatry 192:161-163, 2008 (Pubitemid 351347371)
9. Morrato EH, Druss B, Hartung DM, et al: Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Archives of General Psychiatry 67:17-24, 2010
10. Dorsey ER, Rabbani A, Gallagher SA, et al: Impact of FDA black box advisory on antipsychotic medication use. Archives of Internal Medicine 170:96-103, 2010
11. Lindenmayer JP, Czobor P, Volavka J, et al: Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. American Journal of Psychology 160:290-296, 2003 (Pubitemid 41110454)
12. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601, 2004
13. Huskamp HA, Deverka PA, Epstein AM, et al: The effect of incentive-based formularies on prescription-drug utilization and spending. New England Journal of Medicine 349:2224-2232, 2003 (Pubitemid 37485139)
14. Soumerai SB: Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Affairs 23:135-146, 2004
15. Polinski JM, Wang PS, Fischer MA: Medicaid's prior authorization program and access to atypical antipsychotic medications. Health Affairs 26:750-760, 2007
16. Donohue JM, Huskamp HA, Zuvekas SH: Dual eligibles with mental disorders and Medicare part D: how are they faring? Health Affairs 28:746-759, 2009
17. Carpenter WT, Buchanan RW: Lessons to take home from CATIE. Psychiatric Services 59:523-525, 2008
18. Tandon R, Carpenter WT, Davis JM: First-and second-generation antipsychotics: learning from CUtLASS and CATIE. Archives of General Psychiatry 64:977-978, 2007 (Pubitemid 47230621)
19. Frank RG, Zeckhauser RJ: Custom-made versus ready-to-wear treatments: behavioral propensities in physicians' choices. Journal of Health Economics 26:1101-1127, 2007 (Pubitemid 350166636)
20. Coscelli A: The importance of doctors' and patients' preferences in the prescription decision. Journal of Industrial Economics 48:349-369, 2000
21. Schneeweiss S, Glynn RJ, Avorn J, et al: A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. Journal of Clinical Epidemiology 58:98-102, 2005 (Pubitemid 40093118)
22. Hodgkin D, Merrick EL, Hiatt D: The relationship of antidepressant prescribing concentration to treatment duration and cost. Journal of Mental Health Policy and Economics 15:3-11, 2012
23. Hodgkin D, Volpe-Vartanian J, Merrick EL, et al: Customization in prescribing for bipolar disorder. Health Economics 21:653-668, 2011
24. Merrick EL, Hodgkin D, Panas L, et al: Is customization in antidepressant prescribing associated with acute phase treatment adherence? Journal of Pharmaceutical Health Services Research 3:11-16, 2011
25. Leslie DL, Rosenheck RA: Diversity versus concentration in antipsychotic drug selection. Journal of Mental Health Policy and Economics 11:107-112, 2008
26. AMA Physician Masterfile. Chicago, American Medical Association, 2008
27. Rosenheck RA, Leslie DL, Sindelar J, et al: Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry 163:2080-2089, 2006 (Pubitemid 46114227)
28. Donohue JM, Morden NE, Gellad WF, et al: Sources of regional variation in Medicare Part D drug spending. New England Journal of Medicine 366:530-538, 2012
29. Berenson A: Lilly to pay up to $500 million to settle claims. New York Times, Jan 4, 2007
30. Mojtabai R, Olfson M: National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry 67:26-36, 2010
31. Taub AAL, Kolotilin A, Gibbons RS, et al: The Diversity of Concentrated Prescribing Behavior: An Application to Antipsychotics. Cambridge, Mass, National Bureau of Economics Research, 2011
32. Schiff GD, Galanter WL: Promoting more conservative prescribing. JAMA 301:865-867, 2009
33. Sansone RA, McDonald S, Prutzman C, et al: The comfort level of internists with the prescription of psychotropic medication. International Journal of Psychiatry in Medicine 36:85-92, 2006 (Pubitemid 47104374)
34. Jones MI, Greenfield SM, Bradley CP: Prescribing new drugs: qualitative study of influences on consultants and general practitioners. British Medical Journal 323:378-381, 2001 (Pubitemid 32762465)
35. de Bakker DH, Coffie DSV, Heerdink ER, et al: Determinants of the range of drugs prescribed in general practice: a crosssectional analysis. BMC Health Services Research 7:132, 2007
36. Aparasu RR, Bhatara V, Gupta S: US national trends in the use of antipsychotics during office visits, 1998-2002. Annals of Clinical Psychiatry 17:147-152, 2005 (Pubitemid 41176801)
37. Lieberman JA: Use of antipsychotics in primary care. Journal of Clinical Psychiatry 5:3-8, 2003
38. Kilbourne AM, Goodrich D, Miklowitz DJ, et al: Characteristics of patients with bipolar disorder managed in VA primary care or specialty mental health care settings. Psychiatric Services 61:500-507, 2010
39. Kniesner TJ, Powers RH, Croghan TW: Provider type and depression treatment adequacy. Health Policy 72:321-332, 2005 (Pubitemid 40614683)
40. Hermann RC, Yang D, Ettner SL, et al: Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997. Psychiatric Services 53:425-430, 2002
41. Correll CU, Manu P, Olshanskiy V, et al: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765-1773, 2009
42. McEvoy JP, Lieberman JA, Stroup TS, et al: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 163:600-610, 2006 (Pubitemid 44464569)
43. Kornfield R, Donohue JM, Berndt ER, et al: Promotion of prescription drugs to consumers and providers, 2001-2010. PLoS ONE 8:e55504, 2013
44. Donohue JM, Berndt ER: Direct-to-consumer advertising and choice of antidepressant. Journal of Public Policy and Marketing 23:115-127, 2004
45. Berndt ER, Bui LT, Reiley DR, et al: Information, marketing, and pricing in the US antiulcer drug market. American Economic Review 85:100-105, 1995
46. Van den Bulte C, Lilien GL: Medical innovation revisited: social contagion versus marketing effort. American Journal of Sociology 106:1409-1435, 2001 (Pubitemid 33295223)